Advertisement

Supply Chain



The Food and Drug Administration will prolong its review of Roche's multiple sclerosis drug Ocrevus by another three months, reports Reuters.

Before the Affordable Care Act (ACA) became law, health plans relied on an employer-centric model that was focused entirely on groups rather than members.

Advertisement

Most Read

Advertisement
Advertisement